secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2022-04-22T23:59:59+00:00
Accession:  0000950170-22-006012
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta to host April 25 conference call to discuss Phase 1 data for NKX101 and NKX019
--------------------------------------------------------------------------------

- Conference call scheduled for April 25, 2022 at 8:00 a.m. ET to review preliminary clinical data.
- NKX101 and NKX019 are engineered NK cell therapy candidates in ongoing Phase 1 trials.
- Leading investigators from the two clinical trials will join management for the discussion.
- Webcast and accompanying slides available on Nkarta’s website with replay for ~4 weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022006012/0000950170-22-006012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022006012/nktx-20220422.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-006012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer